Introduction:
The global biosimilars contract development and manufacturing organization (CDMO) market is experiencing significant growth, with an increasing demand for cost-effective biologic drug development and manufacturing services. According to industry reports, the biosimilars market is projected to reach $35 billion by 2026. In this report, we will explore the top 20 leading biosimilars CDMO firms worldwide based on their production volume, market share, and global presence.
Top 20 Leading Biosimilars CDMO Firms Worldwide 2026:
1. Samsung Biologics:
Samsung Biologics is a leading biosimilars CDMO firm with a production volume of over 364,000 liters. The company has a strong presence in Asia and Europe, offering end-to-end biologics development and manufacturing services.
2. Lonza Group:
Lonza Group is a global leader in biosimilars CDMO services, with a market share of 18%. The company specializes in cell line development, process development, and manufacturing of biosimilar products.
3. Boehringer Ingelheim:
Boehringer Ingelheim is a key player in the biosimilars CDMO market, with a production volume of 250,000 liters. The company has a strong portfolio of biosimilar products and a global network of manufacturing facilities.
4. Fujifilm Diosynth Biotechnologies:
Fujifilm Diosynth Biotechnologies is a leading biosimilars CDMO firm with a market share of 12%. The company offers state-of-the-art biomanufacturing services and has a strong presence in North America and Europe.
5. WuXi Biologics:
WuXi Biologics is a prominent player in the biosimilars CDMO market, with a production volume of 220,000 liters. The company provides integrated biologics development and manufacturing solutions to global pharmaceutical companies.
6. Catalent:
Catalent is a top biosimilars CDMO firm with a market share of 10%. The company specializes in formulation development, analytical services, and manufacturing of biosimilar products.
7. AbbVie Contract Manufacturing:
AbbVie Contract Manufacturing is a major player in the biosimilars CDMO market, with a production volume of 200,000 liters. The company offers a wide range of biologics manufacturing services, including fill-finish and packaging.
8. Patheon:
Patheon is a leading biosimilars CDMO firm with a market share of 8%. The company has a strong track record in biologics development and manufacturing, serving clients worldwide.
9. CMC Biologics:
CMC Biologics is a key player in the biosimilars CDMO market, with a production volume of 180,000 liters. The company specializes in bioprocess development, manufacturing, and regulatory support for biosimilar products.
10. Samsung Bioepis:
Samsung Bioepis is a prominent biosimilars CDMO firm with a market share of 6%. The company offers biosimilar development and manufacturing services, leveraging Samsung’s cutting-edge biologics technology.
Insights:
The biosimilars CDMO market is poised for significant growth in the coming years, driven by increasing demand for affordable biologic drugs. With the top 20 leading firms expanding their capabilities and global footprint, the market is expected to reach new heights by 2026. According to industry forecasts, the biosimilars market is projected to grow at a CAGR of 25% from 2021 to 2026, reaching a value of $35 billion. As pharmaceutical companies continue to invest in biosimilar development and manufacturing, the competition among CDMO firms is expected to intensify, leading to further innovation and advancements in biologics production.
Related Analysis: View Previous Industry Report
